Effect of semaglutide on kidney function across different levels of baseline HbA1c, blood pressure, body weight and albuminuria in SUSTAIN 6 and PIONEER 6
Ellen M. Apperloo(Dialyse Centrum Groningen), Hiddo J.L. Heerspink(University Medical Center Groningen), Blaz Vrhnjak(Novo Nordisk (Denmark)), Johannes F.E. Mann(Katholische Stiftungshochschule München), Anja Birk Kuhlman(University of Copenhagen), Katherine R. Tuttle(Providence Regional Medical Center Everett), Søren Rasmussen(Novo Nordisk (Denmark)), Peter Rossing(Steno Diabetes Centers), David Z.I. Cherney(University Health Network)
Cited by 16
Related Papers
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
|New England Journal of Medicine|2019|6k
Dapagliflozin in Patients with Chronic Kidney Disease
|New England Journal of Medicine|2020|5.2k
Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes
|New England Journal of Medicine|2020|2.6k